Dr. Ephraim E. Parent, MD
Nuclear Medicine (Nuclear Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 1,107
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nuclear Medicine Physician primary
FL license ME137212 -
Nuclear Radiology Physician
MO license 2013009624
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mayo Clinic Jacksonville, FL
Medical groups
- Mayo Clinic Jacksonville (1,615 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,107
- Services billed
- 5,029
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Gallium ga-68, dotatate, diagnostic, 0.1 millicurie | 1,667 | 30 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 483 | 437 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 458 | 424 |
| Gallium ga-68 gozetotide, diagnostic, (locametz), 1 millicurie | 349 | 53 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 346 | 179 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 166 | 166 |
| Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging | 163 | 163 |
| Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 157 | 155 |
| Nuclear medicine study whole body with ct scan | 115 | 97 |
| Nuclear medicine study of bone and/or joint whole body | 62 | 61 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 7 companies reported 20 payments worth $34,311 in total to this clinician.
| Blue Earth Diagnostics | $27,993 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $4,479 |
| Telix Pharmaceuticals | $1,440 |
| Progenics Pharmaceuticals, Inc. | $139 |
| GE Healthcare | $117 |
| Novartis Pharmaceuticals Corporation | $115 |
| Siemens Medical Solutions USA, Inc. | $28.77 |
| Consulting Fee | $19,404 |
|---|---|
| Travel and Lodging | $10,960 |
| Honoraria | $3,300 |
| Food and Beverage | $647 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Blue Earth Diagnostics Oct 4, 2025 | Travel and Lodging POSLUMA · Diagnostic Imaging · travel to Barcelona, Spain · in-kind | $10,072 |
| Blue Earth Diagnostics Dec 5, 2025 | Consulting Fee Axumin · Diagnostic Imaging | $7,925 |
| Blue Earth Diagnostics Nov 2, 2025 | Consulting Fee | $4,950 |
| E.r. Squibb & Sons, L.l.c. Oct 9, 2025 | Consulting Fee | $4,479 |
| Blue Earth Diagnostics Apr 17, 2025 | Honoraria POSLUMA · Diagnostic Imaging | $3,300 |
| Telix Pharmaceuticals Mar 13, 2025 | Consulting Fee | $1,200 |
| Blue Earth Diagnostics Mar 21, 2025 | Consulting Fee Axumin · Diagnostic Imaging | $850 |
| Blue Earth Diagnostics Oct 4, 2025 | Travel and Lodging POSLUMA · Diagnostic Imaging · travel to Barcelona, Spain · in-kind | $808 |
| Blue Earth Diagnostics Oct 4, 2025 | Travel and Lodging POSLUMA · Diagnostic Imaging · travel to Barcelona, Spain · in-kind | $80.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $552,232 in research payments for these studies, mostly to the institutions running them.
- Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT05595460 - LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumor
Novartis Pharmaceuticals Corporation - Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Novartis Pharmaceuticals Corporation - A Phase I, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.